Last updated: August 5, 2026
ISOVUE-300 is a mature, FDA-approved iodinated contrast medium containing iopamidol at 300 mg iodine/mL. Bracco Diagnostics markets it primarily for computed tomography, angiography, and other intravascular imaging procedures. Its commercial profile is driven by procedure volume, hospital purchasing contracts, supply reliability, and manufacturing economics rather than patent exclusivity. Public sources do not disclose product-level ISOVUE-300 revenue, profitability, or unit volumes, so its financial trajectory must be assessed through market structure, regulatory status, competitive pricing, and Bracco’s broader contrast-media business.
What is ISOVUE-300 and how is it used?
ISOVUE-300 is a nonionic, low-osmolar, water-soluble contrast agent containing iopamidol. The product is supplied as an injectable solution with an iodine concentration of 300 mg/mL.
FDA-approved uses include:
- Contrast-enhanced computed tomography of the head and body
- Digital subtraction angiography
- Peripheral and visceral angiography
- Intra-arterial digital subtraction angiography
- Other radiographic procedures requiring intravascular iodinated contrast
The 300 mg iodine/mL concentration occupies a high-volume segment of the contrast market because it supports routine CT imaging while limiting iodine load relative to higher-concentration products. The FDA label identifies iopamidol as a nonionic contrast agent and provides dosing ranges by procedure, patient age, body region, and imaging modality (U.S. Food and Drug Administration [FDA], 2023).
ISOVUE-300 product profile
| Attribute |
Product information |
| Brand |
ISOVUE-300 |
| Active ingredient |
Iopamidol |
| Strength |
300 mg iodine/mL |
| Dosage form |
Sterile injectable solution |
| Therapeutic category |
Iodinated radiographic contrast agent |
| Primary users |
Hospitals, imaging centers, radiology departments |
| U.S. marketer |
Bracco Diagnostics Inc. |
| FDA pathway |
Approved new drug application |
| Main applications |
CT, angiography, digital subtraction angiography |
| Biosimilar relevance |
None; ISOVUE-300 is a small-molecule contrast agent |
| Refill or retail market |
Minimal; primarily institutional |
What is the FDA regulatory status of ISOVUE-300?
ISOVUE-300 is an approved prescription imaging product distributed through institutional and hospital channels. Its use is governed by the FDA-approved labeling, including warnings concerning hypersensitivity reactions, acute kidney injury risk, extravasation, thyroid effects, and cardiovascular or neurologic complications associated with intravascular administration (FDA, 2023).
The product is not a biologic and does not qualify for biosimilar competition. Competitive products enter through abbreviated or full drug-approval pathways applicable to non-biologic contrast agents. Depending on the formulation, concentration, manufacturing process, and labeling, competitors may pursue generic or alternative branded approvals.
The product’s mature regulatory status reduces clinical adoption risk. Hospitals and radiology groups have extensive experience with iopamidol, and switching decisions generally depend on price, supply, injector compatibility, clinical protocols, and contract terms.
What is the Orange Book status of ISOVUE-300?
ISOVUE-300’s commercial protection is not dependent on a current patent monopoly. The original composition and formulation exclusivity associated with iopamidol date to an earlier development period, and any original patent protection has expired.
The FDA Orange Book is the principal public source for patents and regulatory exclusivity associated with approved drug products. Mature contrast agents such as ISOVUE-300 generally have limited or no commercially meaningful Orange Book patent protection compared with newer specialty drugs (FDA, 2024).
| Protection category |
ISOVUE-300 assessment |
| Active-ingredient patent |
Expired |
| New chemical entity exclusivity |
Expired |
| Current market exclusivity |
Not commercially material |
| Orange Book litigation exposure |
Low based on mature product status |
| Formulation patent risk |
Limited for the established product |
| Manufacturing know-how |
Potentially relevant |
| Contract and supply barriers |
Commercially relevant |
The absence of meaningful patent protection does not eliminate competitive barriers. Sterile manufacturing capacity, quality systems, regulatory filings, hospital contracts, distribution networks, and inventory requirements remain important.
When does ISOVUE-300 lose exclusivity?
ISOVUE-300 has already passed the period in which conventional small-molecule patent or regulatory exclusivity would control market entry. The product’s current commercial position is therefore post-exclusivity.
No single future loss-of-exclusivity date is likely to produce a sharp revenue event comparable to a patented oncology or immunology product. Generic and branded competition can enter incrementally, and the timing depends on FDA approvals, manufacturing capacity, and hospital formulary decisions.
The most important commercial question is not whether exclusivity will expire. It is how quickly lower-priced alternatives gain purchasing share in hospital tenders and group purchasing organization contracts.
How many patents protect ISOVUE-300?
The relevant patent estate is limited from a practical commercial perspective. The original iopamidol composition patents are expired, and ISOVUE-300 does not have the type of active, layered patent portfolio associated with a recently launched drug.
Potentially relevant intellectual-property categories include:
- Manufacturing processes for iopamidol
- Purification and impurity-control methods
- Sterile filling and packaging
- Container-closure systems
- Automated injector compatibility
- Supply-chain and quality-control procedures
These rights may affect manufacturing economics or operational replication, but they generally do not prevent an approved competitor from marketing an equivalent iopamidol injection.
Which companies compete with ISOVUE-300?
ISOVUE-300 competes within the broader market for nonionic iodinated contrast media. The primary competitive products include iopamidol, iohexol, iopromide, ioversol, and iodixanol formulations.
| Product family |
Active ingredient |
Representative company |
| ISOVUE |
Iopamidol |
Bracco |
| OMNIPAQUE |
Iohexol |
GE HealthCare |
| ULTRAVIST |
Iopromide |
Bayer |
| OPTIRAY |
Ioversol |
Guerbet |
| VISIPAQUE |
Iodixanol |
GE HealthCare |
| Generic iopamidol products |
Iopamidol |
Multiple manufacturers and distributors |
The closest direct competitors are products with the same or similar iodine concentration and comparable indications. In routine CT, hospitals may treat several nonionic low-osmolar agents as clinically substitutable. The competitive decision then shifts to acquisition cost, service levels, clinician preference, injector systems, and contract rebates.
ISOVUE-300 compared with OMNIPAQUE 300
OMNIPAQUE 300 contains iohexol and is a major competing product in CT and angiography. Both products are established nonionic, low-osmolar agents with broad institutional use.
| Factor |
ISOVUE-300 |
OMNIPAQUE 300 |
| Active ingredient |
Iopamidol |
Iohexol |
| Iodine concentration |
300 mg/mL |
300 mg/mL |
| Market status |
Mature branded product |
Mature branded product |
| Clinical substitution |
High in many routine settings |
High in many routine settings |
| Main commercial differentiators |
Price, supply, contracts, local protocol |
Price, supply, contracts, local protocol |
| Biosimilar risk |
None |
None |
| Patent-driven pricing power |
Low |
Low |
The products are not identical, and institutions may maintain modality-specific protocols. In routine imaging, however, purchasing departments often view them as competing options within the same low-osmolar contrast category.
What market dynamics affect ISOVUE-300 demand?
Demand is closely tied to imaging procedure volume. The main demand drivers are:
- CT utilization in emergency, inpatient, and outpatient care.
- Growth in cardiovascular and peripheral angiography.
- Expansion of outpatient imaging centers.
- Hospital capital investment in CT scanners and angiography suites.
- Aging populations and higher chronic-disease prevalence.
- Changes in imaging protocols, including reduced contrast use in selected studies.
Demand can fall when hospitals defer elective procedures, reduce imaging utilization, or adopt lower-dose protocols. It can rise when emergency-department activity, cancer imaging, cardiovascular procedures, or outpatient diagnostic capacity expands.
Unlike drugs prescribed chronically, contrast agents are consumed episodically during procedures. Revenue therefore tracks procedure throughput and purchasing cycles rather than patient persistence or refill rates.
What supply-chain risks affect ISOVUE-300?
Contrast media supply is exposed to concentrated manufacturing and distribution networks. The 2022 Shanghai manufacturing disruption demonstrated that a facility-specific interruption can affect global availability of iodinated contrast agents, including products used in CT imaging (American College of Radiology, 2022).
Key supply-chain risks include:
- Dependence on specialized sterile injectable facilities
- Limited global production redundancy
- Short-term shortages caused by plant outages
- Transportation and packaging constraints
- Hospital inventory depletion during demand surges
- Competition for shared raw materials and production capacity
- Regulatory delays in qualifying alternate manufacturing sites
Supply reliability can temporarily strengthen a supplier’s negotiating position even when the underlying product has no meaningful patent protection. Hospitals may retain a branded product because changing suppliers creates operational risk, protocol changes, and inventory-management costs.
What generic entry risks exist for ISOVUE-300?
Generic entry risk is structurally high because the product is mature and lacks meaningful active exclusivity. The actual commercial threat depends on whether an entrant can meet four requirements:
- FDA approval with adequate quality and labeling
- Reliable sterile injectable manufacturing
- Consistent supply at hospital scale
- Competitive pricing after distribution and contracting costs
Generic entry may reduce net pricing without eliminating branded demand. Bracco can retain share through supply reliability, established clinical familiarity, account relationships, and bundled contracts. Hospitals may also maintain multiple suppliers to reduce shortage exposure.
A low-price entrant could gain share first in price-sensitive outpatient centers and smaller hospitals. Large integrated delivery networks may continue to purchase a branded product if the net price difference is modest or if supply guarantees are stronger.
What patent litigation or Paragraph IV challenges affect ISOVUE-300?
There is no clear basis for treating ISOVUE-300 as an active patent-litigation product. Because its core exclusivity has expired, Paragraph IV litigation is less likely to be commercially significant than in a product with unexpired formulation or method-of-use patents.
Potential disputes would more likely concern:
- FDA approval scope
- Manufacturing processes
- Product quality
- Trade secrets
- Contract terms
- Distribution practices
- Labeling or promotional conduct
The absence of prominent patent litigation is consistent with the product’s maturity and post-exclusivity market position.
How strong is the ISOVUE-300 patent estate?
The patent estate is weak as a source of pricing power but potentially meaningful as an operational barrier.
| Patent-estate dimension |
Assessment |
| Composition-of-matter protection |
Expired |
| Regulatory exclusivity |
Expired |
| Formulation protection |
Limited |
| Method-of-use protection |
Limited for broad labeled uses |
| Manufacturing know-how |
More relevant than patents |
| Litigation leverage |
Low |
| Pricing protection |
Low |
| Supply and quality barriers |
Moderate |
The most defensible commercial assets are likely manufacturing consistency, regulatory compliance, customer relationships, and supply execution rather than exclusionary patent rights.
What is the financial trajectory of ISOVUE-300?
Public financial statements do not separately report ISOVUE-300 sales, gross margin, or operating profit. Bracco is privately held, and its publicly available corporate reporting does not provide a reliable product-level revenue series. A precise historical or forecast revenue trajectory therefore cannot be calculated from public disclosures.
The likely financial pattern is that of a mature institutional pharmaceutical product:
- Stable or declining unit pricing
- Volume linked to imaging procedure growth
- Periodic revenue volatility from shortages and supply interruptions
- Margin pressure from generic and branded competition
- Lower promotional spending than for newly launched medicines
- Continued cash generation if manufacturing utilization remains high
Revenue exposure is meaningful at the portfolio level because contrast media are recurring hospital products, but ISOVUE-300 is unlikely to have the financial concentration associated with a protected specialty medicine.
Bracco’s financial performance is more likely influenced by the combined performance of its contrast-media portfolio, diagnostic imaging systems, international markets, and hospital contracts than by ISOVUE-300 alone.
What licensing deals and commercial partnerships affect ISOVUE-300?
No major publicly disclosed licensing transaction appears to determine ISOVUE-300’s current market position. Its commercial economics are more likely shaped by:
- Hospital supply agreements
- Group purchasing organization contracts
- Regional distribution arrangements
- International marketing rights
- Contract manufacturing or supply relationships
- Imaging-equipment and injector integration
These arrangements may affect net price and market access but are not equivalent to patent licenses. Contract terms are generally private, limiting public assessment of rebate levels and customer-specific profitability.
What generic launch scenarios are most likely for ISOVUE-300?
Scenario 1: Gradual generic erosion
Multiple suppliers enter over time, lowering average selling prices while Bracco retains a portion of demand through established contracts and supply reliability. This is the most typical post-exclusivity outcome.
Scenario 2: Supply-constrained branded retention
A shortage or manufacturing disruption limits effective generic competition. Hospitals preserve incumbent supply relationships, and branded share remains higher than price-based analysis would suggest.
Scenario 3: Accelerated hospital substitution
Large purchasing organizations use competitive tenders to switch substantial volume to lower-cost iopamidol or alternative contrast agents. This scenario creates faster price and share pressure.
Scenario 4: Portfolio-based defense
Bracco protects account share through a broader offering that includes multiple contrast agents, delivery systems, technical support, and international supply coverage. Product-level switching becomes less attractive for hospitals.
Key Takeaways
- ISOVUE-300 is a mature iopamidol-based injectable contrast agent marketed by Bracco Diagnostics.
- Its commercial demand is tied to CT, angiography, and hospital procedure volumes.
- Patent and regulatory exclusivity no longer provide meaningful pricing protection.
- Biosimilar competition is irrelevant because iopamidol is a small-molecule drug.
- Generic and branded contrast products create persistent price pressure.
- Manufacturing capacity, sterile quality systems, supply reliability, and hospital contracts are the main barriers to competition.
- Product-level revenue and profitability are not publicly disclosed.
- The likely financial trajectory is stable-to-declining pricing with volume support from diagnostic imaging growth.
- Supply disruptions can temporarily alter market share and pricing dynamics.
- The central investment issue is Bracco’s broader contrast-media portfolio, not ISOVUE-300 patent exclusivity.
FAQs about ISOVUE-300
Is ISOVUE-300 still commercially available?
Yes. ISOVUE-300 remains an established institutional contrast agent, although availability can vary by region, distributor inventory, and broader iodinated contrast supply conditions.
Is iopamidol the same as ISOVUE-300?
No. Iopamidol is the active ingredient, while ISOVUE-300 is a branded finished product containing iopamidol at 300 mg iodine/mL.
Can hospitals substitute OMNIPAQUE 300 for ISOVUE-300?
Hospitals may use alternative 300 mg iodine/mL nonionic contrast agents when clinically appropriate and consistent with local protocols. Substitution decisions are made by radiology, pharmacy, procurement, and medical staff.
Does ISOVUE-300 have biosimilar competition?
No. Biosimilars apply to biological products. ISOVUE-300 is a small-molecule iodinated contrast injection and faces generic or alternative branded competition instead.
What is the largest commercial risk to ISOVUE-300?
The largest commercial risk is sustained hospital price erosion from competing contrast agents, reinforced by group purchasing contracts and generic entry. Supply interruptions can create short-term volatility in the opposite direction.
References
-
American College of Radiology. (2022). ACR manual on contrast media. https://www.acr.org/Clinical-Resources/Contrast-Manual
-
Bracco Diagnostics Inc. (2023). ISOVUE-300 (iopamidol injection) prescribing information. U.S. Food and Drug Administration.
-
U.S. Food and Drug Administration. (2023). ISOVUE-300: Iopamidol injection, prescribing information. https://www.accessdata.fda.gov
-
U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.fda.gov/drugs/drug-approvals-and-databases/orange-book-data-files
-
U.S. Food and Drug Administration. (2024). Drug shortages database. https://www.accessdata.fda.gov/scripts/drugshortages/
